signific
progress
knowledg
relationship
infecti
diseas
immun
system
relat
asthma
mani
unansw
question
still
remain
respiratori
tract
infect
caus
respiratori
syncyti
viru
rhinoviru
first
two
year
life
still
clearli
associ
later
wheez
asthma
mechan
complet
work
infecti
march
trigger
infect
infanc
progress
diseas
patholog
infant
contract
respiratori
infect
predispos
develop
asthma
review
focus
common
theme
interact
microb
immun
system
present
critic
apprais
evid
date
variou
mechan
wherebi
microb
alter
immun
respons
might
influenc
asthma
discuss
along
new
promis
clinic
practic
prevent
therapi
recent
advanc
util
sensit
pcr
detect
method
allow
rigor
test
causal
hypothesi
viru
infect
lead
asthma
evid
still
equivoc
variou
except
inconsist
clinic
trial
discuss
light
new
guidelin
subject
inclusionexclus
hope
provid
standard
spite
past
failur
vaccin
disappoint
result
clinic
trial
new
strategi
prophylaxi
includ
rna
interfer
target
deliveri
microbicid
offer
larg
dose
hope
world
suffer
increas
incid
asthma
huge
burden
healthcar
cost
loss
qualiti
life
like
asthma
associ
respiratori
infect
inflammatori
immun
respons
complex
incomplet
understood
clearli
see
effect
infect
wheez
asthma
incept
exacerb
dissect
mechanist
detail
challeng
confront
us
decad
alway
hope
complet
understand
cell
cytokin
signal
pathway
involv
along
knowledg
tempor
progress
event
role
regulatori
factor
microrna
lead
effect
treatment
individu
patient
asthma
afflict
million
individu
age
ethnic
group
result
approxim
death
worldwid
million
children
age
diagnos
asthma
us
alon
asthmarel
hospit
near
us
annual
direct
medic
expens
associ
asthma
care
billion
accord
crosssect
intern
studi
conduct
intern
studi
asthma
allergi
childhood
isaac
preval
asthma
symptom
report
yearold
age
group
increas
significantli
among
center
examin
furthermor
nation
surveil
report
identifi
substanti
rise
asthma
attack
within
past
two
decad
addit
direct
impact
asthma
qualiti
life
healthcar
cost
among
young
popul
grow
evid
exist
asthmat
phenotyp
associ
increas
suscept
respiratori
tract
infect
ri
attribut
viru
particularli
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
respiratori
virus
certain
atyp
bacteria
also
suspect
play
part
airway
inflamm
asthma
pathogenesi
chapter
explor
mechan
viral
bacteri
infect
trigger
asthma
exacerb
look
similar
differ
discuss
new
therapeut
strategi
attempt
target
area
advanc
biotechnolog
provid
diagnostician
ultrasensit
method
quantit
realtim
polymeras
chain
reaction
pcr
identifi
respiratori
tract
pathogen
nucleic
acid
sequencebas
amplif
nasba
highthroughput
microarray
chip
virochip
increas
data
collect
order
magnitud
earli
epidemiolog
studi
frequent
suffer
variabl
viral
isol
rate
reli
tissu
cultur
serolog
detect
hrv
rsv
human
influenza
viru
human
parainfluenzaviru
hpiv
human
metapneumoviru
hmpv
enteroviru
mycoplasma
pneumonia
chlamydia
pneumonia
pneumococc
strain
hemophilu
influenza
microbi
pathogen
usual
abund
nasopharyng
aspir
npa
children
adult
activ
asthma
due
technolog
limit
variabl
clinic
criteria
diagnos
asthma
observ
earli
studi
show
weak
correl
respiratori
infect
wheezi
bronchiti
asthma
total
viral
isol
rate
rsv
hrv
hpiv
children
age
low
children
high
children
hospit
admiss
report
asthma
attack
spite
limit
earli
studi
identifi
import
factor
influenc
certain
viru
isol
rate
like
patient
readmiss
statu
season
ill
sensit
detect
method
environment
exposur
parent
smoke
patient
age
controversi
question
whether
viral
infect
caus
asthma
exacerb
asthma
phenotyp
enhanc
suscept
infecti
diseas
still
answer
one
earliest
longitudin
survey
roehampton
studi
conduct
uk
horn
et
al
span
horn
et
al
span
provid
key
inform
regard
potenti
chang
type
pathogen
isol
differ
season
age
despit
lack
hightech
tool
pcr
microarray
extens
studi
found
hrv
hpiv
rsv
predomin
infecti
agent
isol
rsv
infect
highest
among
children
less
four
year
age
occur
often
winter
month
hrv
ill
occur
season
age
recent
report
util
pcr
sensit
method
gener
confirm
find
roehampton
studi
frequent
detect
respiratori
tract
pathogen
acut
lower
respiratori
bronchiti
suggest
microbi
pathogen
trigger
airway
inflamm
stimul
leukocyt
infiltr
importantli
certain
popul
children
wheez
viral
infect
show
symptom
wheez
viral
infect
suggest
immedi
correl
asthmat
phenotyp
respiratori
infect
although
multitud
factor
genet
environ
weather
atop
sensit
could
trigger
asthma
attack
microbi
pathogen
potenti
contribut
persist
episod
asthma
attack
birth
cohort
longitudin
studi
conduct
last
two
decad
also
support
find
horn
et
al
perth
australia
kusel
et
al
follow
infant
birth
first
year
life
assess
incid
acut
respiratori
ill
ari
viral
bacteri
origin
collect
npa
sampl
use
pcr
viral
detect
perth
studi
identifi
hrv
rsv
hcov
piv
predomin
respiratori
pathogen
associ
ari
control
children
healthi
asymptomat
npa
sampl
posit
viral
agent
virus
present
infect
children
hrv
frequent
viru
identifi
three
form
ari
includ
upper
uri
lower
without
wheez
nwlri
lower
respiratori
ill
wheez
wlri
attribut
risk
associ
wlri
measur
degre
specif
pathogen
contribut
sever
respiratori
ill
highest
hrv
rsv
respect
fiveyear
followup
origin
perth
birth
cohort
hrvand
rsvassoci
wheez
lri
correl
statist
signific
currentor
persistentwheez
currentasthma
later
life
skin
prick
test
help
categor
remain
children
follow
group
never
atop
atop
age
two
year
atop
two
year
combin
ari
histori
statu
atop
sensit
children
atop
age
two
acquir
wlri
hrvinfect
found
greatest
likelihood
develop
wheez
age
five
odd
ratio
associ
group
nearli
doubl
one
wlri
report
cohort
studi
kusel
et
al
provid
evid
hrvinduc
wlri
earli
sensit
risk
factor
current
persist
wheez
asthma
age
five
report
jackson
et
al
support
correl
wheezi
rhinoviru
infect
develop
asthma
children
age
six
among
children
examin
studi
known
childhood
origin
asthma
coast
madison
wisconsin
children
develop
childhood
asthma
sixth
year
wheez
ill
attribut
either
hrv
rsv
third
year
life
increas
risk
develop
asthma
age
six
particular
children
wheezi
hrvinduc
ill
age
three
subsequ
becam
asthmat
age
six
hrvinduc
wheez
observ
within
first
second
third
year
life
increas
risk
asthma
age
six
led
conclus
rhinovirusassoci
ill
infanc
earli
predictor
subsequ
develop
asthma
age
six
agreement
kusel
et
al
stein
et
al
respiratori
ill
without
wheez
statist
correl
develop
asthma
age
six
number
longitudin
studi
implic
hrv
promin
viral
pathogen
asthma
etiolog
causal
direct
rsvinduc
ill
asthma
appear
difficult
defin
sinc
sever
rsvinduc
diseas
appear
affect
age
environ
atopi
error
refer
sourc
found
tabl
summar
studi
design
popul
group
type
respiratori
tract
pathogen
isol
intern
clinic
studi
adult
children
current
time
four
swedish
cohort
studi
conduct
sigur
et
al
prospect
follow
children
infanc
age
compar
agematch
control
subject
exposur
rsv
associ
significantli
higher
preval
asthma
rsvexpos
vs
control
allerg
rhinoconjunct
age
rsvexpos
vs
control
sensit
allergen
age
rsvexpos
vs
control
occurr
rsvinduc
bronchiol
within
first
year
life
associ
develop
asthma
age
twoyear
prospect
studi
conduct
finland
use
pcr
detect
method
identifi
rsv
hrv
virus
major
etiolog
agent
acut
expiratori
wheez
hospit
children
month
year
age
among
case
acut
expiratori
wheez
involv
singl
respiratori
viru
coinfect
sever
differ
virus
compris
case
studi
found
notic
agedepend
variat
viral
agent
preval
rsv
infect
children
less
month
age
age
group
wherea
enterovirus
hrv
preval
children
month
old
unfortun
screen
atyp
bacteria
perform
assess
preval
c
pneumonia
pneumonia
contrast
tucson
children
respiratori
studi
conduct
stein
et
al
found
rsvassoci
lri
wheez
episod
age
independ
risk
factor
wheez
asthma
age
age
differ
swedish
tucson
studi
design
may
account
discrep
result
age
tucson
questionnair
studi
enrol
healthi
children
first
year
life
swedish
studi
investig
primarili
infant
less
six
month
old
hospit
rsvinduc
bronchiol
consequ
swedish
studi
examin
incid
sever
rsvinduc
respiratori
ill
result
enhanc
airway
obstruct
limit
airway
function
furthermor
tucson
studi
util
immunofluoresc
viral
cultur
without
pcr
may
result
miss
detect
viral
pathogen
exampl
children
acquir
virusneg
lri
age
three
found
increas
risk
frequent
wheez
age
eight
compar
healthi
control
moreov
lri
caus
agent
includ
rhinoviru
contribut
low
proport
report
lri
statist
correl
frequent
wheez
age
three
find
conflict
studi
identifi
hrv
predomin
caus
wheezi
lri
children
rang
age
report
found
rel
low
pcr
detect
atyp
respiratori
bacteria
c
pneumonia
pneumonia
children
despit
design
differ
sweden
finland
tucson
clinic
studi
implic
rsv
import
pathogen
subsequ
develop
earli
childhood
asthma
human
rhinovirus
hrv
caus
common
cold
acut
respiratori
ill
adult
children
hrv
relat
enterovirus
like
polioviru
echoviru
coxsackieviru
posit
sens
singlestrand
rna
genom
hrv
encas
within
highli
variabl
protein
capsid
compos
icosahedr
arrang
copi
viral
protein
canyonlik
depress
circl
vertic
made
five
triangular
repeat
bind
viru
cell
receptor
occur
near
canyon
hrva
hrvb
divers
exce
serotyp
identifi
continu
circul
suggest
emerg
strain
may
new
rather
previous
unrecogn
highli
sensit
genom
sequenc
rtpcr
gener
replac
serotyp
diagnost
research
use
method
discov
third
viral
subgroup
call
hrvc
associ
fall
winter
asthma
flare
children
infect
mostli
adult
children
older
three
year
hrv
enter
upper
respiratori
tract
via
aerosol
droplet
transmiss
hand
contact
hrv
ill
usual
notic
within
first
three
day
accompani
symptom
common
cold
includ
nasal
congest
cough
sneez
headach
sore
throat
replic
epitheli
cell
occur
optim
temperatur
lead
investig
consid
hrv
exclus
etiolog
agent
upper
respiratori
tract
infect
recent
evid
howev
indic
hrv
equal
import
lower
respiratori
tract
pathogen
symptom
hrv
infect
often
persist
lower
airway
adult
elderli
yet
evid
support
hypothesi
hrv
caus
chronic
infect
limit
sinc
earli
longitudin
studi
fail
identifi
hrv
serotyp
therefor
still
unclear
whether
persist
hrvinduc
ari
result
chronic
new
infect
differ
serotyp
support
argument
hrv
caus
chronic
infect
followup
evalu
coast
studi
particip
found
consecut
recurr
hrv
infect
serotyp
uncommon
sinc
larg
number
serotyp
recircul
popul
reinfect
serotyp
unlik
similar
highli
divers
viral
pathogen
antigen
divers
could
serv
mean
evad
adapt
immun
despit
differ
nucleotid
sequenc
antivir
drug
suscept
capsid
proteincod
nearli
hrv
serotyp
share
common
cellular
receptor
viral
attach
human
epitheli
cell
viruscel
surfac
attach
subsequ
infect
mediat
bind
intercellular
adhes
usual
function
leukocyt
migrat
antigenindepend
adhes
lymphocyt
interact
predomin
receptor
use
circul
hrv
serotyp
receptor
compat
appear
limit
hrv
host
rang
receptor
becom
recogn
attach
molecul
pathogen
includ
rhinoviru
coxsacki
viru
speci
recent
rsv
evid
suggest
express
modul
hrv
infect
make
promis
target
antivir
therapi
respiratori
syncyti
viru
member
paramyxovirida
famili
relat
etiolog
agent
mump
measl
parainfluenza
one
lead
caus
pediatr
geriatr
respiratori
diseas
rsv
infect
recur
throughout
life
longterm
immun
vaccin
thu
far
unsuccess
rsv
infect
result
approxim
death
annual
person
age
account
estim
respiratoryrel
healthcar
visit
rsv
mortal
morbid
increas
among
infant
immunocomprom
pulmonari
hypertens
popul
senior
particular
remain
high
risk
rsv
infect
may
expos
nosocomi
infect
hospit
longterm
care
facil
notori
rsv
vaccin
failur
use
formalininactiv
rsv
firsv
stimul
immun
much
like
salk
polio
vaccin
unfortun
firsv
fail
elicit
neutral
antibodi
matur
place
tcell
mediat
immunopatholog
enhanc
current
two
fdaapprov
prophylact
neutral
antibodi
rsv
glycoprotein
g
avail
highrisk
infant
effect
vaccin
therapi
avail
gener
popul
rsv
diseas
onset
resembl
hrv
infect
fever
wheez
sever
rsv
protein
credit
suppress
antivir
respons
includ
nonstructur
protein
disrupt
jakstat
signal
express
result
human
rsv
poor
induc
antivir
ifn
respons
primari
subsequ
rsv
infect
lead
epitheli
damag
lymphocyt
infiltr
airway
inflamm
singlestrand
negativesens
rna
genom
rsv
associ
ribonucleoprotein
rnp
complex
consist
nucleocapsid
n
phosphoprotein
p
larg
l
rnadepend
rna
polymeras
upon
virion
assembl
filament
bud
infect
epitheli
cell
bilipid
envelop
layer
deriv
host
cell
interact
matrix
protein
surround
rnp
visual
hallmark
rsv
infect
monolay
cultur
cell
format
syncytia
resembl
multinucl
cell
fusion
neighbor
cell
initi
rsv
glycoprotein
f
g
small
hydrophob
protein
sh
plasmid
transfect
three
viral
protein
found
suffici
syncytium
format
f
g
numer
role
disrupt
hostcel
respons
infect
interf
antivir
signal
investig
individu
rsv
protein
provid
evid
rsv
capac
alter
host
immun
respons
stimul
chronic
inflammatori
respons
virus
respiratori
pathogen
caus
chronic
infect
contribut
asthma
although
less
promin
report
hrv
rsv
longitudin
studi
examin
asthma
exacerb
consist
recov
detect
pcr
atyp
bacteria
chlamydophila
pneumonia
mycobacterium
pneumonia
c
pneumonia
etiolog
agent
atyp
pneumonia
detect
serolog
cultur
antigen
detect
complement
fixat
found
case
acut
exacerb
children
infect
c
pneumonia
report
high
adult
pcr
detect
use
similarli
pneumonia
contribut
pneumonia
infect
predomin
caus
tracheobronch
like
agent
chronic
respiratori
infect
c
pneumonia
pneumonia
found
possess
numer
mechan
disrupt
innat
humor
cellmedi
immun
respons
cellular
responsesmost
hrv
serotyp
rsv
strain
caus
littl
cellular
injuri
bronchial
epitheli
cell
cultur
compar
infect
influenza
viru
epitheli
cell
necrosi
occur
cellular
debri
accumul
sever
rsv
infect
major
hrvand
rsvinduc
patholog
attribut
indirect
stimul
host
innat
adapt
immun
cell
vitro
cultur
assay
anim
model
system
vital
resourc
studi
diseas
pathogenesi
unfortun
us
primat
cell
select
permiss
larg
number
hrv
serotyp
cell
rodent
mammal
lack
primat
receptor
hrv
absorpt
thu
support
replic
serotyp
defin
majorgroup
hinder
studi
majorgroup
hrv
vivo
use
anim
model
rodent
cell
semipermiss
remain
minorgroup
consequ
minortyp
strain
use
develop
rhinoviru
asthma
exacerb
balbc
mice
rsv
infect
rel
ineffici
adult
rodent
high
viral
load
rsv
pfu
requir
produc
patholog
chang
intranas
intratrach
inocul
despit
limit
murin
model
virusinduc
asthma
exacerb
provid
great
deal
inform
regard
hrv
rsv
pathogenesi
bronchoalveolar
lavag
bal
fluid
recov
minorgroup
hrvinfect
mice
often
demonstr
neutrophilia
upregul
rant
regul
activ
normal
tcell
express
secret
macrophag
inflammatori
increas
product
tcell
chemokin
within
first
two
day
infect
chemokin
elev
murin
rsv
infect
includ
monocyt
chemoattract
protein
interferoninduc
protein
interferongamma
keratinocyt
cytokin
kc
earli
flux
chemokin
hrv
rsv
infect
mice
thought
contribut
lymphocyt
activ
recruit
neutrophil
macrophag
eosinophil
translat
mous
studi
human
subject
gern
et
al
group
recruit
human
patient
inocul
majorgroup
observ
cellular
respons
hrv
infect
surprisingli
cellular
profil
inocul
differ
greatli
among
atop
asthmat
nonatop
subject
neutrophil
found
predomin
cell
recov
bal
fluid
neutrophilia
present
group
acut
cold
ill
signific
groupspecif
differ
observ
peak
nasal
viral
titer
cold
symptom
score
bronchial
biopsi
hrvinfect
asthma
patient
display
tcell
infiltr
site
infect
yet
similar
infiltr
absent
hrvinfect
subject
without
asthma
gern
et
al
also
observ
elev
secret
neutrophil
chemotaxin
granulocyt
colonystimul
factor
gcsf
sputum
sampl
infect
asthma
patient
neutrophil
recruit
correl
virusmedi
influx
asthmat
nonatop
individu
overal
lack
cellular
differ
suggest
replic
enhanc
atop
asthmat
individu
level
eosinophil
sputum
significantli
higher
asthmat
baselin
day
inocul
nasal
lavag
fluid
acut
infect
follow
convalesc
although
eosinophil
frequent
elev
nonatop
asthma
patient
compar
healthi
control
group
without
asthma
eosinophil
observ
persist
lower
airway
asthma
subject
convalesc
stage
infect
similar
eosinophil
persist
appar
healthi
individu
asthmat
significantli
increas
secret
nasal
lavag
fluid
baselin
compar
healthi
control
cumul
vitro
vivo
studi
identifi
specif
characterist
virusinduc
asthma
exacerb
includ
airway
tcell
infiltr
virusinduc
recruit
neutrophil
enhanc
eosinophilia
airway
recoveri
rv
infect
unlik
hrv
particularli
experiment
infect
rsv
conduct
extens
human
subject
june
two
report
use
gmpqualiti
wildtyp
rsv
human
experiment
infect
healthi
young
adult
age
inocul
nostril
instil
either
high
log
tcid
low
log
tcid
rsv
dose
observ
day
neither
control
inocul
subject
demonstr
sever
ill
symptom
lower
respiratori
diseas
cough
short
breath
wheez
eight
subject
given
high
dose
five
subject
given
low
dose
shed
viru
one
eight
day
inocul
inocul
individu
exhibit
mild
system
ill
fever
chill
fatigu
respiratori
symptom
remain
local
upper
respiratori
tract
studi
specif
measur
viral
titer
level
viral
protein
f
g
report
infiltr
cell
profil
thu
cellular
associ
experiment
rsv
inocul
human
directli
compar
murin
vitro
studi
nasal
bronchial
lavag
earlier
clinic
studi
provid
evid
infiltr
cell
chemokin
profil
rsvinfect
patient
similar
hrvinfect
murin
model
human
subject
neutrophil
abund
nasal
lavag
rsvinfect
adult
infant
respons
rsvinfect
earli
cytokin
chemokin
like
rant
upregul
upper
respiratori
tract
lastli
detect
level
eosinophil
factor
associ
eosinophil
airway
inflamm
like
eosinophil
cation
protein
eotaxin
observ
highest
among
infant
rsvbronchiol
compar
control
nonrsv
bronchiol
signific
eosinophil
virusinduc
asthma
wide
debat
sinc
eosinophil
often
preval
area
epitheli
damag
like
contribut
eosinophil
inflamm
convers
observ
murin
model
demonstr
protect
role
eosinophil
viral
clearanc
secret
ribonucleas
antivir
factor
eosinophil
degranul
releas
eosinophil
peroxidas
epo
shown
vitro
enhanc
presenc
virus
cocultur
experi
antigenpres
cell
macrophag
dendrit
cell
tcell
davoin
et
al
demonstr
addit
hrv
rsv
hpiv
result
elev
epo
andor
leukotrien
releas
addit
hrv
rsv
stimul
product
presenc
dendrit
cell
tcell
eosinophil
absent
report
suggest
eosinophilia
secret
eosinophil
cation
protein
ecp
rant
potenti
predictor
asthma
diseas
sever
consequ
virusinduc
eosinophilia
may
play
signific
role
asthma
exacerb
molecular
mechanismsrsv
observ
exacerb
pulmonari
stress
immunocompromis
individu
increas
airway
resist
potenti
hypoxemia
rsv
infect
alter
cytokin
product
result
chronic
inflamm
respiratori
failur
death
cellular
immunodefici
vari
age
person
year
age
alarm
respiratori
pulmonari
death
rsvassoci
rsv
employ
multipl
defens
innat
adapt
antivir
respons
capac
alter
allerg
respons
interfer
lymphocyt
activ
rsvinfect
infant
suppress
product
elev
suffici
stimul
ige
respons
disrupt
typei
ifn
respons
g
f
rsv
protein
promot
viral
replic
surviv
preliminari
studi
show
transloc
nucleu
rel
express
enhanc
silenc
smallinterf
rna
rsvinfect
lung
adenocarcinoma
epitheli
cell
import
apoptosi
activ
respons
suppress
inappropri
respons
ifnregulatori
factor
shown
regul
tcell
differenti
ifn
influenc
dendrit
cell
matur
cytokin
product
impair
ifn
express
subsequ
differenti
could
result
inflammatori
diseas
altern
rsv
g
protein
may
disrupt
cytokin
balanc
secret
form
g
sg
contain
domain
mimic
chemokin
induc
product
lead
eosinophilia
mechan
requir
examin
need
determin
role
g
protein
inflammatori
diseas
collect
antagonist
rsv
protein
give
rsv
capac
directli
indirectli
impair
immun
cell
activ
skew
profil
rhinoviru
infect
trigger
cascad
event
lead
overproduct
mucu
activ
upregul
chemokin
cytokin
particular
potent
proinflammatori
cytokin
tumor
necrosi
factor
alpha
produc
macrophag
upon
activ
macrophag
deriv
either
primari
monocyt
activ
correl
anoth
respiratori
viru
sendai
parainfluenza
viru
use
model
virusinduc
asthma
exacerb
brown
norway
rat
infect
sendai
viru
substanti
increas
express
subunit
impli
function
activ
upon
viru
infect
respiratori
epitheli
cell
show
increas
express
sever
pattern
recognit
receptor
prr
includ
tolllik
receptor
respons
hrv
rsv
respect
rsvmediat
overexpress
associ
sensit
epitheli
cell
result
enhanc
product
stimul
bacteri
lipopolysaccharid
lastli
hrv
rsv
util
receptor
viral
attach
upregul
could
enhanc
viral
infect
hrv
observ
select
enhanc
membranebound
suppress
express
secret
recognit
bind
requir
effect
viral
infect
either
hrv
rsv
therapeut
applic
attempt
target
block
monoclon
antibodi
applic
block
antibodi
show
promis
hrv
infect
reduc
rv
infect
symptom
length
diseas
human
subject
similarli
blockag
neutral
monoclon
antibodi
attenu
rsv
infect
epitheli
cell
vitro
similar
rsv
infect
hrv
infect
often
result
reduct
mrna
ratio
seen
experiment
infect
human
subject
rel
weak
respons
also
attribut
sever
respiratori
diseas
longer
viral
shed
human
trial
asthmat
individu
increas
risk
hrv
infect
instead
symptom
clinic
ill
extend
longer
time
report
sever
healthi
nonasthmat
cohabit
partner
acquir
hrv
infect
healthi
control
usual
mild
upper
respiratori
ill
three
day
asthma
patient
develop
upper
lower
respiratori
tract
symptom
five
day
distort
respons
expect
predispos
subject
sever
allerg
reaction
hrv
infect
vitro
stimul
upregul
pbmc
atop
asthmat
contrast
usual
observ
decreas
pbmc
healthi
control
likewis
rsv
infect
ovalbuminallerg
mice
airway
hyperrespons
enhanc
accompani
upregul
increas
eosinophilia
lung
upon
inhal
ovalbumin
hrv
also
demonstr
attenu
ifn
respons
disrupt
activ
mechan
may
differ
infect
decreas
nuclear
transloc
compar
cell
infect
vesicular
stomat
viru
vsv
known
induc
respons
moreov
immunoblot
display
loss
homodim
form
cell
compar
vsvinfect
cell
four
hour
seven
hour
postinfect
interestingli
express
prrlike
melanoma
differentiationassoci
gene
mitochondri
antivir
signal
mav
protein
unchang
lysat
infect
four
seven
hour
postinfect
togeth
evid
suggest
disrupt
nuclear
transloc
suppress
product
infect
without
disrupt
either
mav
figur
illustr
mechan
rsv
hrv
infect
may
skew
profil
enhanc
respons
allerg
asthmat
individu
therapeut
approach
respiratori
viral
infectionsdevelop
efficaci
costeffect
antivir
hrv
rsv
proven
continu
challeng
research
clinician
tabl
hrv
capsid
surfac
protein
highli
variabl
among
serotyp
passiv
immun
like
provid
margin
protect
sinc
major
hrvinduc
ill
healthi
individu
lead
hospit
coldlik
symptom
peak
within
day
usual
subsid
within
week
therapeut
benefit
hrv
intervent
would
need
significantli
outweigh
risk
associ
deliv
treatment
immun
vaccin
fail
clinic
trial
firsv
associ
danger
vaccin
deliveri
unpredict
could
result
symptom
seriou
convers
respiratori
viral
agent
contribut
develop
asthma
prophylact
use
antivir
potenti
prevent
ari
well
chronic
ill
current
antivir
drug
target
step
involv
viral
propag
suppress
spread
infect
includ
attach
replic
protein
synthesi
releas
viral
progeni
illustr
figur
altern
supplement
interferon
promot
antivir
immunolog
effect
therebi
decreas
cell
suscept
intranas
interferon
demonstr
effect
prophylact
potenti
enteroviru
hrv
studi
rsvinfect
murin
model
intranas
administr
plasmid
encod
decreas
neutrophilia
pulmonari
inflamm
associ
rsvinduc
diseas
sever
promis
antivir
agent
physic
disrupt
interact
virion
host
cell
receptor
theori
prevent
attach
viru
reduc
abil
fuse
infect
cell
human
monoclon
antibodi
rsv
f
protein
palivizumab
current
pharmacolog
agent
fdaapprov
administr
highrisk
infant
prevent
sever
lri
tabl
summar
viral
target
antivir
compound
like
proteas
viral
protein
inhibitor
undergon
undergo
clinic
studi
potenti
therapeut
applic
human
recent
clinic
trial
elimin
sever
promis
inadequ
ineffect
antivir
candid
exampl
proteas
inhibitor
rupintrivir
demonstr
prophylact
efficaci
reduc
viral
load
experiment
hrv
infect
fail
protect
natur
hrv
infect
result
futur
clinic
applic
pursu
despit
disappoint
firsv
vaccin
rupintrivir
altern
antivir
strategi
investig
includ
use
larg
chemicallibrari
screen
identifi
specif
smallmolecul
inhibitor
deliveri
smallinterf
rna
silenc
viral
protein
gene
express
complementari
pharmacolog
agent
altern
passiv
immun
small
molecul
inhibitor
viral
protein
antagonist
show
promis
tissuecultur
anim
model
altern
experiment
studi
proceed
clinic
applic
may
success
devincenzo
et
al
first
group
demonstr
proofofconcept
applic
rnai
rna
interfer
protect
rsv
deliv
sirna
respiratori
tract
human
subject
given
experiment
rsv
infect
rnaibas
therapi
shown
promis
vitro
anim
model
variou
human
diseas
predominantli
cancer
rodent
model
intranas
deliveri
sirna
nucleocapsid
n
protein
day
rsv
inocul
reduc
lung
viral
titer
load
least
two
log
gene
silenc
wellconserv
rsv
n
protein
disrupt
viral
replic
impair
rsv
rna
polymeras
first
sirna
deliv
human
via
intranas
rout
specif
combat
microbi
pathogen
random
phase
ii
studi
conduct
devincenzo
et
al
decreas
rsv
infect
experiment
rsvinocul
subject
compar
placebotr
control
diagnos
two
culturebas
assay
day
postinfect
mean
viral
load
pfuml
decreas
approxim
log
detect
qrtpcr
antivir
effect
found
independ
preexist
rsvneutral
antibodi
cytokin
concentr
thu
exhibit
potenti
therapeut
use
healthi
adult
howev
low
statist
power
insuffici
sampl
number
hinder
studi
reliabl
evalu
antivir
doserespons
respect
viral
load
diseas
symptom
entir
term
studi
remain
attract
antivir
candid
sinc
advers
affect
observ
normal
adult
human
investig
need
test
efficaci
rnai
natur
infect
applic
infant
rsvrisk
group
postinfect
therapeut
antiinflammatori
agentshrv
rsv
highli
infecti
ubiquit
respiratori
pathogen
erad
either
speci
near
futur
highli
unlik
cope
virusinduc
bronchiol
varieti
antiinflammatori
pharmacolog
agent
bronchodil
steroid
recommend
suscept
individu
reduc
airway
inflamm
nation
health
organ
guidelin
often
recommend
inhal
corticosteroid
ic
primari
treatment
recurr
asthma
follow
shortor
longact
saba
laba
cysteinylleukotrien
cyslt
receptor
agonist
ltra
ic
act
reduc
asthma
symptom
help
improv
forc
expiratori
volum
second
fev
peak
expiratori
flow
rate
pefr
although
ic
demonstr
potenc
inflammatori
diseas
continu
prefer
drug
manag
asthma
symptom
evid
lack
support
ic
prevent
virusinduc
wheez
corticosteroidunrespons
subpopul
clinic
studi
uk
children
age
month
hospit
wheezi
ari
oral
corticosteroid
prednisolon
administr
five
consecut
day
fail
reduc
diseas
sever
hospit
length
significantli
accord
retrospect
us
studi
steroidinsensit
frequent
adolesc
popul
year
age
patient
sever
asthma
fail
respond
glucocorticosteroid
therapi
inconsist
respons
ic
like
result
genet
variabl
atop
famili
histori
airway
fibrosi
accumul
sever
epitheli
damag
current
insuffici
inform
assess
effect
ic
virusinduc
ill
controversi
efficaci
ic
virusinduc
ari
continu
recent
clinic
studi
suggest
leukotrien
receptor
antagonist
may
allevi
virusinduc
bronchiol
two
clinic
trial
cyslt
known
montelukast
demonstr
efficaci
rsvinduc
asthma
exacerb
compar
placebo
bisgaard
et
al
monitor
children
month
old
day
compar
effect
chewabl
tablet
montelukast
rsvinduc
bronchiol
compar
placebo
random
doubleblind
placebocontrol
studi
subject
receiv
monteukast
report
fewer
symptom
diseas
sever
significantli
less
placeboreceiv
control
popul
posthoc
analysi
similar
extens
studi
bisgaard
et
al
reveal
compar
therapeut
effect
montelukast
rsvbronchiol
furthermor
kim
et
al
specif
investig
antiinflammatori
effect
montelukast
infant
period
analyz
eosinophil
degranul
measur
secret
eosinophil
biomark
eosinophilderiv
neurotoxin
edn
edn
stabl
eosinophil
biomark
therefor
better
represent
eosinophil
inflammatori
activ
eosinophil
count
alon
reason
group
use
edn
level
estim
diseas
sever
recurr
wheez
kim
et
al
observ
significantli
higher
level
edn
rsvinfect
popul
uninfect
control
furthermor
patient
receiv
cours
montelukast
significantli
lower
level
edn
placebotr
group
base
evid
montelukast
could
use
treat
rsv
bronchiol
howev
investig
need
understand
antivir
mechan
differ
subpopul
respond
drug
challeng
opportun
asthma
therapywhil
infect
viru
bacteria
may
play
role
wheez
airway
inflamm
hyperact
hrv
rsv
primari
etiolog
agent
associ
acut
respiratori
ill
asthma
exacerb
children
hospit
asthma
exacerb
wheez
episod
examin
yearlong
prospect
crosssect
studi
bueno
air
age
rang
month
year
pcr
util
detect
viru
bacteria
nasopharyng
aspir
sampl
agreement
other
maffey
et
al
found
viru
bacteria
case
rsv
hrv
pneumonia
c
pneumonia
increas
sensit
pcr
enabl
detect
pathogen
would
otherwis
nondetect
cultur
method
addit
method
recruit
diagnos
examin
ari
subject
becom
standard
better
comparison
studi
howev
sever
factor
continu
caus
variabl
communitybas
studi
environment
econom
social
variabl
continu
challeng
diagnostician
healthcar
worker
collect
data
studi
obtain
control
difficult
due
semiinvas
procedur
comparison
must
often
made
asymptomat
individu
furthermor
statist
power
studi
reduc
rel
small
number
elig
cooper
particip
cohort
investig
studi
infant
older
children
hospit
sever
ari
symptom
addit
studi
less
sever
case
done
determin
mild
rsv
infect
associ
wheez
despit
strong
evid
link
asthma
respiratori
infect
direct
causal
viral
infect
asthma
still
heatedli
debat
grow
bodi
evid
support
causal
relationship
hrv
similar
relationship
rsv
difficult
prove
sinc
virtual
children
infect
rsv
age
two
therefor
develop
asthma
like
depend
genet
andor
atop
factor
et
al
recent
report
new
evid
associ
rsv
infect
develop
recurr
wheez
nonatop
infant
worldwid
multicent
investig
prophylact
deliveri
palivizumab
decreas
rel
risk
recurr
wheez
nonatop
infant
surprisingli
palivizumab
fail
improv
wheez
outcom
infant
famili
atop
genet
background
one
first
investig
evalu
protect
effect
palivizumab
recurr
wheez
evid
et
al
suggest
earlylif
rsv
infect
significantli
predispos
nonatop
popul
recurr
wheez
addit
investig
util
prophylaxi
includ
passiv
immun
neutral
antibodi
antivir
candid
need
better
understand
contribut
viral
infect
develop
asthma
smallinterf
rna
neutral
antibodi
rsv
fusion
inhibitor
show
promis
vitro
murin
model
feasibl
broadus
applic
remain
test
asthma
epidem
persist
wheez
condit
continu
increas
cost
healthcar
world
await
applic
effect
prophylact
prevent
microbeassoci
respiratori
ill
viral
mechan
may
contribut
asthma
exacerb
target
antivir
rsv
hrv
tabl
clinic
studi
investig
respiratori
tract
infect
adult
zealand
prospect
cohort
jan
atop
asthmat
adult
